Aclaris Therapeutics is a physician-led biopharmaceutical company focused on dermatological and immuno-inflammatory diseases. The company's commercial product, ESKATA (hydrogen peroxide) topical solution, 40% (w/w), or ESKATA, is a proprietary formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. The company has acquired RHOFADE (oxymetazoline hydrochloride) cream, 1%, or RHOFADE, which includes a license to certain intellectual property for RHOFADE, from Allergan Sales, LLC. RHOFADE has been approved for the topical treatment of persistent facial erythema (redness) associated with rosacea in adults.

Bank of Commerce is a bank holding company. Through its subsidiary, the company provides a range of financial services and products for business and retail customers. The services the company provides include those offered by banks of similar size and character in California. The company's principal deposit products include the following types of accounts; checking, interest-bearing checking, money market, savings and certificates of deposit. The company also provides sweep arrangements, commercial loans, construction loans, term loans, consumer loans, safe deposit boxes, and electronic banking services. The company does not provide trust services or international banking services.

Fastenal is engaged in the wholesale distribution of industrial and construction supplies. The company is a distributor of fasteners and related industrial and construction supplies. This includes threaded fasteners, bolts, nuts, screws, studs, and related washers, as well as miscellaneous supplies and hardware, such as pins, machinery keys, concrete anchors, metal framing systems, wire rope, strut, rivets, and related accessories. The company's fastener product line is primarily sold under the Fastenal product name.

Homology Medicines is a genetic medicines company. The company's proprietary platform is designed to utilize its human hematopoietic stem-cell derived adeno-associated virus vectors (AAVHSCs) to deliver single administration genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The properties of the company's proprietary suite of 15 AAVHSCs enable it to focus on a method of gene editing called gene correction, either through the replacement of an entire diseased gene in the genome with a whole functional copy or the repair of individual mutated nucleotides, nucleotides.

Molecular Templates is a clinical-stage company focused on the discovery and development of biologic therapeutic for cancer and other serious diseases. The company utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies (ETBs). The company is developing ETBs for various targets, including CD20, CD38, HER2, PD-L1, CTLA-4, SLAMF-7, and CD45. CD20 is central to B cell malignancies and is clinically validated as a target for the treatment of lymphomas and autoimmune disease. CD38 has been validated as a clinical target in the treatment of various myeloma. PD-L1 is central to immune checkpoint pathways and is a target expressed in a variety of solid tumor cancers.